Cargando…
Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling
Interleukin-6 (IL-6) is a critical regulator of the immune system and has been widely implicated in autoimmune disease. Here, we describe the discovery and characterization of olokizumab, a humanized antibody to IL-6. Data from structural biology, cell biology and primate pharmacology demonstrate th...
Autores principales: | Shaw, Stevan, Bourne, Tim, Meier, Chris, Carrington, Bruce, Gelinas, Rich, Henry, Alistair, Popplewell, Andrew, Adams, Ralph, Baker, Terry, Rapecki, Steve, Marshall, Diane, Moore, Adrian, Neale, Helen, Lawson, Alastair |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011921/ https://www.ncbi.nlm.nih.gov/pubmed/24670876 http://dx.doi.org/10.4161/mabs.28612 |
Ejemplares similares
-
Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F
por: Adams, Ralph, et al.
Publicado: (2020) -
Model-Based Optimal Design and Execution of the First-Inpatient Trial of the Anti-IL-6, Olokizumab
por: Kretsos, K, et al.
Publicado: (2014) -
Interleukin 6/gp130 axis promotes neural invasion in pancreatic cancer
por: Suzuki, Hidetaka, et al.
Publicado: (2022) -
Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment
por: Bure, Irina V., et al.
Publicado: (2020) -
Genetic and Clinical Factors Associated with Olokizumab Treatment in Russian Patients with Rheumatoid Arthritis
por: Mikhaylenko, Dmitry S., et al.
Publicado: (2022)